Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity

DOI10.1007/s10985-010-9163-zzbMath1322.62109OpenAlexW2053628500WikidataQ42655294 ScholiaQ42655294MaRDI QIDQ746098

Xiudong Lei, Ying Yuan, Guosheng Yin

Publication date: 15 October 2015

Published in: Lifetime Data Analysis (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1007/s10985-010-9163-z

zbMATH Keywords

survival analysisefficacytoxicityadaptive randomizationphase II trialtime-to-event endpoint

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15) Sequential statistical design (62L05)

Cites Work

• Unnamed Item
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• The two-armed bandit with delayed responses
• The doubly adaptive biased coin design for sequential clinical trials
• Designs for Group Sequential Phase II Clinical Trials
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• One-Sample Multiple Testing Procedure for Phase II Clinical Trials
• The Randomized Play-the-Winner Rule in Medical Trials
• Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
• Bayesian Analysis of Binary and Polychotomous Response Data
• The Theory of Response‐Adaptive Randomization in Clinical Trials
• Response-Adaptive Randomization for Survival Trials: The Parametric Approach

This page was built for publication: Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity